News | August 10, 2025
Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Cenexi reports an EBITDA breakeven for the quarter
Vasograin Plus represents a major advancement in the treatment of migraine
This will be Aster’s fifth hospital in Bengaluru
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Subscribe To Our Newsletter & Stay Updated
